Trial Profile
Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 17 Aug 2017 Primary endpoint (Progression-free survival duration) has been met,as per published in the Alimentary Pharmacology and Therapeutics.
- 17 Aug 2017 Primary endpoint (Stable disease rate) has been met, as per results published in the Alimentary Pharmacology and Therapeutics.
- 17 Aug 2017 Results published in the Alimentary Pharmacology and Therapeutics